Navigation Links
MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review of Safety Data Enables Trial Continuation Without any Modifications
Date:2/1/2017

STOCKHOLM, Sweden, Feb. 01, 2017 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today announces that the independent Data Monitoring Committee (DMC) held its fourth and final scheduled meeting and recommended continuation of the ongoing randomized, double-blind phase IIa study (MIV-711-201) based on a review of unblinded safety data

The objective of MIV-711-201 is to evaluate the safety, tolerability and efficacy of six months of treatment with MIV-711 in patients with moderate knee osteoarthritis. As part of the study, an independent DMC is periodically scheduled to review the unblinded safety data from the trial. Based on the last scheduled review of the accumulated safety data, which took place after the first 200 subjects had completed 3 months of treatment, the DMC has recommended that the phase IIa trial of osteoarthritis should continue without any modifications.

It is expected that data from MIV-711-201 will be available in the third quarter of 2017 and that data from the ongoing extension study, MIV-711-202, will be available in the first half of 2018.

MIV-711 is being developed as a DMOAD, i.e. a drug to slow or reverse the progressive degeneration of joints affected by OA. There are no DMOADs approved for use currently, and the standard of care for OA patients is based on analgesics, with the potential for associated side effect risks such as gastrointestinal bleeding and opioid dependency, and changes in life style. DMOADs for osteoarthritis therefore represent a very large and attractive market opportunity. Medivir estimates that the US market alone is greater than USD 6 billion annually for a drug that impacts disease progression, even if its use was restricted just to patient populations with moderate osteoarthritis in weight-bearing joints.

Further information on the study can be accessed on www.clinicaltrials.gov, ref# NCT02705625.

For further information, please contact:

Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

This information is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 1 February 2017.

About Medivir

Medivir is a research based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir's class B share is listed on the Nasdaq Stockholm Mid Cap List.

CONTACT:

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/miv-711-osteoarthritis-trial--successful-fourth-independent-review-of-safety-data-enables-trial-cont,c2178118

The following files are available for download:

http://mb.cision.com/Main/652/2178118/622108.pdf

Press release (PDF)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/miv-711-osteoarthritis-trial-successful-fourth-independent-review-of-safety-data-enables-trial-continuation-without-any-modifications-300400247.html


'/>"/>
SOURCE Medivir
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth
2. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
3. Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
4. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
5. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
6. September is National Aging Month: Resources Available on Importance of Treatment for Cataracts, Osteoarthritis and Diabetes
7. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis
8. Pharmalink Acquires Novel Therapeutic Product Candidate for Treating Inflammation Associated With Osteoarthritis
9. Global Osteoarthritis Market 2015-2019 - Increased Competition in the Market With Abbott Laboratories, Johnson & Johnson, Novartis & Pfizer Dominating
10. Townsend Announces Launch Of New Osteoarthritis Knee Brace
11. Ampio Pharmaceuticals Announces Update of STRIDE Study for the Investigation of Pain Associated with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
(Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... On May 24, ... which narrowly passed the U.S. House on May 4, would result in 23 million ... under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and helps educate ... is on hiking in American. Viewers can reconnect with America as it explores some ... , Many consumers have looked for an inventive new place for a family vacation, ...
(Date:5/26/2017)... ... 26, 2017 , ... Centennial-based BluSky Restoration Contractors announced that ... Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa ... part of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... Medical Center CEO Mary Ellen, hospital employees, and town officials to celebrate the ... The facility was developed by Rendina as part of its ongoing relationship with ...
(Date:5/24/2017)... Diego, California (PRWEB) , ... May 24, 2017 ... ... care through innovative medical image management and interpretation, has received U.S. Food and ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical ...
Breaking Medicine News(10 mins):